Agilon Health (AGL) to Release Earnings on Wednesday

Key Points

• Agilon Health will report Q1 2026 results after the market closes on Wednesday, May 6, with analysts projecting EPS of $1.06 and revenue of about $1.41 billion and an earnings call at 4:30 PM ET.
• The company missed its last quarter's EPS and shows negative return on equity and net margin, and analysts forecast steeply negative full-year EPS (about $-6 this year and $-5 next year), signaling ongoing profitability concerns.
• Shares recently jumped ~10.5% to open near $28, the stock carries an average analyst rating of "Hold" with a consensus target of $40.23, and major institutions (notably Goldman Sachs and AQR) significantly increased their positions.

Agilon Health (NYSE:AGL - Get Free Report) is expected to be posting its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Agilon Health to post earnings of $1.06 per share and revenue of $1.4101 billion for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Agilon Health (NYSE:AGL - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.19). Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%.The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.46 billion. On average, analysts expect Agilon Health to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Agilon Health Trading Up 10.5%

Shares of NYSE AGL opened at $27.98 on Wednesday. The stock's 50 day moving average price is $16.43 and its two-hundred day moving average price is $17.88. Agilon Health has a 52-week low of $7.48 and a 52-week high of $119.50. The stock has a market capitalization of $466.15 million, a P/E ratio of -1.18 and a beta of 0.33. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12.

Analyst Ratings Changes

Several analysts have issued reports on AGL shares. Weiss Ratings restated a "sell (e+)" rating on shares of Agilon Health in a research note on Monday, April 20th. Barclays cut their price objective on Agilon Health from $25.00 to $12.50 and set an "underweight" rating on the stock in a research note on Friday, February 27th. Deutsche Bank Aktiengesellschaft set a $33.00 price objective on Agilon Health and gave the company a "hold" rating in a research note on Thursday, April 9th. Benchmark upped their price objective on Agilon Health to $13.00 and gave the company a "buy" rating in a research note on Thursday, April 2nd. Finally, Wells Fargo & Company upped their price objective on Agilon Health from $25.00 to $37.50 and gave the company an "overweight" rating in a research note on Friday, February 27th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $40.23.

Institutional Trading of Agilon Health

A number of institutional investors and hedge funds have recently made changes to their positions in AGL. Goldman Sachs Group Inc. lifted its holdings in shares of Agilon Health by 196.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company's stock valued at $13,812,000 after buying an additional 13,283,930 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Agilon Health by 1,346.6% in the fourth quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company's stock valued at $7,033,000 after buying an additional 9,505,837 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Agilon Health by 30.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,019,002 shares of the company's stock valued at $5,523,000 after buying an additional 1,893,434 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Agilon Health by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 7,177,477 shares of the company's stock valued at $4,944,000 after buying an additional 35,054 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Agilon Health by 41.3% in the third quarter. Bank of America Corp DE now owns 5,414,614 shares of the company's stock valued at $5,577,000 after buying an additional 1,581,284 shares during the period.

Agilon Health Company Profile

Agilon Health NYSE: AGL is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.